Finally, we assessed the correlation between the altmetric attention scores and the number of citations for the retrieved data. Results Spanning January 2015 to July 2023, the study encompassed 466 articles concerning [177Lu]Lu-PSMA therapy for prostate cancer. Predominant citation accolades gravitated...
e17057#Background:Results from the VISION trial (NCT03511664) led to the approval of lutetium-177 (177Lu)–PSMA-617 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This trial excluded patients with baseline cytopenias, thus safety in this frequently encountered patient...
23, 2022, the FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto; Novartis), which is referred to in nuclear medicine literature as 177Lu–prostate-specific membrane antigen–617 (177Lu PSMA-617), for the treatment of PSMA-positive metastatic castration resistant p...
Lutetium- 177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a ... Calopedos,JS R.,Chalasani,... 被引量: 0发表: 0年 Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific...
e17049#Background:177Lu–PSMA is a radiolabeled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA). It has been approved for use in metastatic castration-resistant prostate cancer (mCPRC) in 3/2022, based on VISION study. The Food and Drug Ad...
1 other channel Advanced Prostate Cancer Expert Opinion / Interview · March 15, 2022 Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Interview with Oliver Sartor MD Save Recommend Share Facebook Twitter LinkedIn Print Email × You must be a m...
In the last 3years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This therapy combines the radionuclide Lutetium-177, which has...
Real world data of 177 Lutetium-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC): Analysis of patients treated from 2 large reference c... Real world data of 177 Lutetium-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC): Analysis of patients treated from 2...
MCNP6 simulates two different treatments: Brachytherapy with 125I seeds and radiolabeled 177Lu-PSMA. • A 3D model of the anatomy of a real anonymized patient is created from the segmentation of CT images. • Dose given to the prostate and each surrounding organ is obtained for both treatm...
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) Radionuclide therapyProstate cancerLutetiumPSMANuclear medicineTheranosticsProstate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be... C Kratochwil,WP Fendler,M Eiber,....